Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Highlights the global burden of chronic kidney disease and calls for a prospective randomized controlled trial to evaluate the impact of sodium intake on CKD progression.
According to the Global Burden of Diseases, Injuries, and Risk Factors Study 2017, chronic kidney disease (CKD) affects 9.1% of the population worldwide, with Stages 1 and 2 accounting for >50% of CKD cases [1]. The age-standardized prevalence is higher in females (9.5%) than in males (7.3%), but the incidence of end-stage kidney disease (ESKD) is lower in females. Moreover, the CKD prevalence is very heterogeneous in different areas of the world depending on the sociodemographic situation, the burden of disease being greater in countries with lower socio-economic development. In contrast to many other non-communicable diseases [2], such as ischaemic heart disease or stroke, the global age-standardized mortality rate associated with CKD did not decline substantially during the last decades and CKD remains a major cause of global and cardiovascular mortality. In the survey mentioned above [1], identified CKD risk factors were impaired fasting...
No takes yet. Share an insight, caveat, or question.
Michel Burnier (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: